Patents by Inventor Patrick Engelberts

Patrick Engelberts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies
    Patent number: 11970544
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: April 30, 2024
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • ANTIBODIES BINDING TO CD30 AND CD3
    Publication number: 20240132607
    Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 25, 2024
    Inventors: David SATIJN, Patrick ENGELBERTS, Kristel KEMPER, Esther C. W. BREIJ, Simone OOSTINDIE, Farshid ALEMDEHY
  • ANTIBODIES CAPABLE OF BINDING TO ROR2 AND BISPECIFIC ANTIBODIES BINDING TO ROR2 AND CD3
    Publication number: 20230365714
    Abstract: The present invention relates to antibodies binding to ROR2, including bispecific antibodies binding to ROR2 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: October 1, 2021
    Publication date: November 16, 2023
    Inventors: Louise Koopman, Patrick ENGELBERTS, David SATIJN, Jan Hermen DANNENBERG
  • Antibodies binding to CD30 and CD3
    Patent number: 11814437
    Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: November 14, 2023
    Assignee: GENMAB A/S
    Inventors: David Satijn, Patrick Engelberts, Kristel Kemper, Esther C. W. Breij, Simone Oostindie, Farshid Alemdehy
  • BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER
    Publication number: 20230257479
    Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
    Type: Application
    Filed: September 11, 2020
    Publication date: August 17, 2023
    Inventors: David SATIJN, Esther C.W. BREIJ, Bart E.C.G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN, Reshma Abdulla RANGWALA, Sri GHATTA, Ruud BRAKENHOFF, Rieneke VAN DE VEN
  • ANTIBODIES BINDING TO CD30 AND CD3
    Publication number: 20230132049
    Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
    Type: Application
    Filed: October 6, 2022
    Publication date: April 27, 2023
    Inventors: David SATIJN, Patrick Engelberts, Kristel Kemper, Esther C.W. Breij, Simone OOSTINDIE, Farshid ALEMDEHY
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20230027394
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: January 26, 2023
    Inventors: Rik RADEMAKER, Isil Altintas, Patrick Engelberts, Janine Schuurman, Paul Parren
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20220389101
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: December 8, 2022
    Inventors: Rik RADEMAKER, Isil ALTINTAS, Patrick ENGELBERTS, Janine SCHUURMAN, Paul PARREN
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20220380464
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: December 1, 2022
    Inventors: Rik RADEMAKER, Isil ALTINTAS, Patrick ENGELBERTS, Janine SCHUURMAN, Paul PARREN
  • ANTIBODIES
    Publication number: 20220324980
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 15, 2022
    Publication date: October 13, 2022
    Inventors: Louise KOOPMAN, Patrick ENGELBERTS, Dennis VERZIJL, Edward N. VAN DEN BRINK, Rik RADEMAKER, Sieto BOSGRA, Frederikke L. EGEROD, David SATIJN, Esther C. W BREIJ
  • Humanized or chimeric CD3 antibodies
    Patent number: 11359015
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: June 14, 2022
    Assignee: GENMAB A/S
    Inventors: Rik Rademaker, Isil Altintas, Patrick Engelberts, Janine Schuurman, Paul Parren
  • Antibodies
    Patent number: 11261254
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: March 1, 2022
    Assignee: GENMAB A/S
    Inventors: Louise Koopman, Patrick Engelberts, Dennis Verzijl, Edward N. Van Den Brink, Rik Rademaker, Sieto Bosgra, Frederikke L. Egerod, David Satijn, Esther C. W. Breij
  • ANTIBODIES
    Publication number: 20220049013
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: June 21, 2021
    Publication date: February 17, 2022
    Inventors: David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN
  • ANTIBODIES
    Publication number: 20220048999
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: October 5, 2021
    Publication date: February 17, 2022
    Inventors: Louise KOOPMAN, Patrick ENGELBERTS, Dennis VERZIJL, Edward N. VAN DEN BRINK, Rik RADEMAKER, Sieto BOSGRA, Frederikke L. EGEROD, David SATIJN, Esther C. W. BREIJ
  • Antibodies
    Patent number: 11130819
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: September 28, 2021
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • ANTIBODIES
    Publication number: 20210292418
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 17, 2021
    Publication date: September 23, 2021
    Inventors: Louise KOOPMAN, Patrick ENGELBERTS, Dennis VERZIJL, Edward N. VAN DEN BRINK, Rik RADEMAKER, Sieto BOSGRA, Frederikke L. EGEROD, David SATIJN, Esther C. W. BREIJ
  • ANTIBODIES
    Publication number: 20210230296
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: April 12, 2021
    Publication date: July 29, 2021
    Inventors: David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN
  • Antibodies
    Patent number: 11008399
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 18, 2021
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • ANTIBODIES
    Publication number: 20210070877
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: October 22, 2020
    Publication date: March 11, 2021
    Inventors: David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN
  • ANTIBODIES
    Publication number: 20200277397
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 9, 2020
    Publication date: September 3, 2020
    Inventors: David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN